The involvement of TTR against Aβ aggregation and toxicity in the context of Alzheimer’s disease is now well established and future efforts to exploit the role of TTR as therapeutic tool are expected. This evidence concerns the gene TTR and early-onset autosomal dominant Alzheimer disease.